Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | PDE8A | O60658 | 6/20 | 0.54 |
| ▸ | SLC29A1 | Q99808 | 8/20 | 0.53 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL946430 | 0.88 | MEN1 (0.58) | MEN1LMNAKMT2AADORA2AADORA1 | |
| SCHEMBL29853379 | 0.88 | MEN1 (0.58) | MEN1LMNAKMT2AADORA2AADORA1 | |
| SCHEMBL17144109 | 0.88 | ADORA2A (0.60) | ADORA2AADORA1PDE8ASLC29A1PDE4A | |
| SCHEMBL23388239 | 0.84 | ADORA2A (0.67) | MEN1LMNAKMT2AADORA2AADORA1 | |
| SCHEMBL13596787 | 0.83 | PDE8A (0.62) | ADORA2APDE8APDE4APDE4BPDE4C | |
| SCHEMBL21076723 | 0.81 | PDE8A (0.57) | ADORA2APDE8APDE4APDE4BPDE4C | |
| SCHEMBL7204689 | 0.81 | PDE8A (0.60) | ADORA2APDE8APDE4APDE4BPDE4C | |
| SCHEMBL1146681 | 0.81 | YTHDC1 (0.67) | ADORA2APDE8APDE4APDE4BPDE4C | |
| SCHEMBL2060472 | 0.80 | PDE4A (0.67) | ADORA2AADORA1PDE8APDE4APDE4B | |
| SCHEMBL25511867 | 0.80 | MEN1 (0.51) | MEN1LMNAKMT2AADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148436-A2 | NOVEL SMALL MOLECULE IMMUNE AGONISTS AND IMMUNE TARGETING COMPOUNDS AND APPLICATION THEREOF | SHENZHEN UNIVERSITY (CN) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148436-A2 | NOVEL SMALL MOLECULE IMMUNE AGONISTS AND IMMUNE TARGETING COMPOUNDS AND APPLICATION THEREOF | IFNG, IFNAR1, STING1 | MEN1 4060/4885LMNA 4873/4885KMT2A 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.